Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with intermediate- or high-risk primary myelofibrosis, or myelofibrosis following polycythemia vera or essential thrombocythemia, and platelet counts below 50 × 10⁹/L.
LAMPGEN ANALYSIS
Why it matters
The platelet threshold targets a population with severe thrombocytopenia and limited options.
What research teams should watch
Verify disease risk, a contemporaneous platelet count, and bleeding risk when documenting eligibility.
PRIMARY RECORDS